The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease
Abstract
Parkinson's Disease (PD) is characterized by a selective loss of nigrostriatal dopaminergic neurons that results in a marked reduction of dopaminergic nerve terminals in the striatum. Recently, 11 C‐WIN 35,428, a cocaine analogue that specifically labels the dopamine transporter, was developed and can be used to label dopaminergic nerve terminals in vivo by positron emission tomography. In healthy control subjects, binding of 11 C‐WIN 35,428 is highest in the striatum. In addition, 2 symmetrical focal areas of low binding were observed in the midbrain. The cerebellum functioned as an appropriate region for nonspecific binding. The binding of 11 C‐WIN 35,428 in patients with PD (Hoehn‐Yahr II) was compared with that in healthy control subjects by using the (region‐cerebellum)/cerebellum ratio for data acquired 34 to 82 minutes after injection. In control subjects, this ratio varied, at approximately 2, in the striatum. In patients with PD, binding in the posterior putamen was reduced by 78%, whereas the anterior putamen and the caudate nucleus showed a reduction of 59 and 39%, respectively. The reduction in 11 C‐WIN 35,428 binding was highest in the midbrain (84%). The high specific/nonspecific binding ratio and the pronounced reduction in binding in mild PD may permit detection of even earlier stages of PD or presymptomatic individuals with dopaminergic cell loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
The dopamine hypothesis of the reinforcing properties of cocaine
Kuhar, M. J., Ritz, M. C., & Boja, J. W. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90141-g · Cited by 987
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine Systems
Moore, R. Y., & Bloom, F. E. (1978) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.01.030178.001021 · Cited by 926
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 849
Müller-Gärtner, H. W., Links, J. M., Prince, J. L., Bryan, R. N., McVeigh, E., Leal, J. P., Davatzikos, C., & Frost, J. J. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.81 · Cited by 756
Self-citationWong, D. F., Wagner, H. N., Dannals, R. F., Links, J. M., Frost, J. J., Ravert, H. T., Wilson, A. A., Rosenbaum, A. E., Gjedde, A., Douglass, K. H., et al. (1984) · Science · doi:10.1126/science.6334363 · Cited by 697
Self-citationThe Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Cited by
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602
“…reduction in [ 11 C]WIN-35,428 BP in the putamen compared with the caudate nucleus is in keeping with previous observations of greater DA terminal loss in the putamen than in the caudate of patients with PD (Kish et al., 1988; Tedroff et al., 1988; Kaufman and Madras, 1991; Frost et al., 1993).”
BackgroundResultNEUROIMAGING AND NEUROPSYCHOLOGY OF THE STRIATUM
Rauch, S. L., & Savage, C. R. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70343-9 · Cited by 148
Chou, Y.-H., Huang, W.-S., Su, T.-P., Lu, R.-B., Wan, F.-J., & Fu, Y.-K. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.05.002 · Cited by 78
Correlation of Parkinson's disease severity and duration with123I-FP-CIT SPECT striatal uptake
Benamer, H. T. S., Patterson, J., Wyper, D. J., Hadley, D. M., Macphee, G. J. A., & Grosset, D. G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v
Metadata
- Authors
- Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1993-09
- Volume
- 34
- Issue
- 3
- Pages
- 423-431
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2060626983
- Cited by
- 320
- References
- 64
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease. https://app.cochat.ai/papers/10.1002/ana.410340331
- The paper
- Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F. (1993). Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease. Annals of Neurology. https://doi.org/10.1002/ana.410340331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
